Showing 7491-7500 of 7736 results for "".
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Valeant Headquarters Moving to Montreal Regionhttps://practicaldermatology.com/news/20120416-valeant_headquarters_moving_to_montreal_region/2459825/Valeant Pharmaceuticals is relocating its global headquarters to the Montreal region and will establish the Laboratore Dr. Renaud Centre of Excellence—a R&D center for consumer dermatology—in Laval, Quebec. Laboratoire Dr. Renaud and a newly acqu
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- Health plans sue Big Pharma over co-pay couponshttps://practicaldermatology.com/news/20120308-health_plans_sue_big_pharma_over_co-pay_coupons__read_more_health_plans_sue_big_pharma_over_co-pay_coupons_-_fiercepharma_httpwwwfiercepharmacomstoryh/2459850/Pharma's co-pay discounts have their fans--patients, certainly, and companies that have been able to boost prescriptions for high-priced drugs or hang onto sales as brands go off patent. But co-pay coupons and discount cards also have their detractors--namely, insurers and other payers trying to ste
- YBF Beauty Products Debut on Ulta.comhttps://practicaldermatology.com/news/20120307-ybf_beauty_products_debut_on_ultacom/2459853/YBF Beauty , a complete collection of makeup essentials from Stacey Schieffelin, is now available from Ulta.com . The products feature Smart Active Complex, a paraben-free formula, "enriche
- Health Care Fraud Prevention and Enforcement Efforts Net Nearly $4.1Bhttps://practicaldermatology.com/news/20120302-health_care_fraud_prevention_and_enforcement_efforts_net_nearly_41b/2459856/Attorney General Eric Holder and Department of Health and Human Services (HHS) Secretary Kathleen Sebelius today released a new report showing that the government's health care fraud prevention and enforcement efforts recovered nearly $4.1 billion in taxpayer dollars in Fiscal Year (FY) 2011. This